Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 9/20 | 0.55 |
| ▸ | NAMPT | P43490 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | THRB | P10828 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5582566 | 0.92 | MCHR1 (0.65) | MCHR1MAPTTP53LMNAHTR2C | |
| SCHEMBL5582738 | 0.91 | MCHR1 (0.64) | MCHR1MAPTTP53LMNAHTR2C | |
| SCHEMBL5582876 | 0.91 | MCHR1 (0.57) | MCHR1NAMPTMAPTTP53LMNA | |
| SCHEMBL5582954 | 0.86 | MAPT (0.53) | MCHR1NAMPTMAPTTP53LMNA | |
| SCHEMBL5582717 | 0.83 | MCHR1 (0.66) | MCHR1NAMPTMAPTTP53LMNA | |
| SCHEMBL5582579 | 0.83 | MCHR1 (0.65) | MCHR1NAMPTMAPTTP53LMNA | |
| SCHEMBL14454802 | 0.83 | MCHR1 (0.65) | MCHR1NAMPTMAPTHTR2CNPC1 | |
| SCHEMBL5583917 | 0.83 | MCHR1 (0.63) | MCHR1MAPTTP53LMNAHTR2C | |
| SCHEMBL5582844 | 0.83 | MCHR1 (0.67) | MCHR1MAPTHTR2CSMN1; SMN2 | |
| SCHEMBL5582640 | 0.82 | MCHR1 (0.64) | MCHR1NAMPTMAPTHTR2CNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-7115750-B1 | Melanin concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | MC1R, MCHR1, MCHR2 | MCHR1 2/4885NAMPT 1308/4885MAPT 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.